Video B-Roll via On-Demand and Satellite - Health Canada Approves ATRIPLA, The First Once-Daily Single Tablet Regimen For HIV

    TORONTO, Oct. 17 /CNW/ - The following B-Roll is available at the listed
times and coordinates:

    Broadcast Quality MPEG2 file download URL:

    Live Satellite Coordinates:

    DATE OF FEED:      Wednesday October 17, 2007
    TIME OF FEED:      2:00 pm EDT - 2:30 pm EDT
    CO-ORDINATES:      Anik F2 C, Transponder 7B
                       Audio subcarrier 6.2 and 6.8
                       Downlink frequency 3980 vertical
    TOC                CFA TX 1

    STORY SUMMARY: Health Canada has granted approval of ATRIPLA(TM)
(a-trip-la) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil
fumarate 300 mg) for treatment of HIV-1 infection in adults. With this Notice
of Compliance (NOC), ATRIPLA becomes the first ever once daily single tablet
regimen for HIV intended for use as a stand alone therapy or in combination
with other antiretroviral medications in Canada.


    HIV (Human Immunodeficiency Virus) is the virus that causes AIDS
(Acquired Immunodeficiency Syndrome). People with HIV are diagnosed with AIDS
when the virus has damaged their immune system to the point that they may no
longer be able to successfully fight infection.

    2006 marked the 25th anniversary of the start of the AIDS epidemic. The
first cases of HIV/AIDS were reported by the U.S. Centers for Disease Control
and Prevention (CDC) in June 1981.

    In 2006, it was estimated that more than 61,000 people in Canada were
living with HIV infection (including AIDS). Of these, approximately 27% were
estimated to be unaware of their infection.

    Packaging and manufacturing
    HIV patient
    Scientific research and lab
    ATRIPLA animation

    Integrated Communications at (519) 570-2020 (ext. 2237).

    For technical information DURING the satellite feed, please call CNW at
    (416) 863-5615

    CNW Broadcast On-Demand provides free, secure and easy-to-use broadcast
quality material direct from our website to accredited journalists worldwide.
Please contact to get immediate access.
    As with all CNW Broadcast feeds, this release is offered for your free
and unrestricted news use. Comments regarding the content and quality are

For further information:

For further information: CNW BROADCAST, TORONTO, (416) 863-9350

Organization Profile

CNW Video Services

More on this organization

Bristol-Myers Squibb Canada

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890